Home › Products › COVID-19 research › Viral and host sequencing

COVID-19 research

Next-generation sequencing for SARS-CoV-2 research

During viral pandemics, next-generation sequencing (NGS) can be a valuable tool for the characterization and detection of viruses in the environment, animals, and humans (Kustin et al. 2019). Additionally, NGS can provide useful insights to help researchers and clinicians looking to develop the right treatment options. We offer a variety of RNA-sequencing kits for unmatched sensitivity and reproducibility for all of your demanding sequencing applications, including research on SARS-CoV-2.

Monitoring of the environment

Monitoring environmental samples (e.g., tabletops, door handles, and other high touch points) for the presence of harmful pathogens requires a high degree of sensitivity, down to just a few copies of a viral or bacterial genome. Our SMARTer RNA-seq products offer sensitivity to detect trace amounts of RNA, and through randomly primed reverse transcription also enable detection of RNA that is in various stages of degradation. In particular, the SMARTer Pico v3 RNA-seq (the improved version of Pico v2) and SMART-Seq Stranded kits work from inputs of <1 ng total RNA to provide comprehensive RNA transcript profiling.

Understanding the effects of viral infection

Our tools, such as the SMART-Seq v4 PLUS and SMART-Seq Single Cell PLUS kits (the improved versions of our customer-trusted SSv4 and SSsc cDNA-generation kits), can help researchers understand the expression changes that occur in a host as a result of viral infection and treatment—at both the bulk and single-cell level, respectively—to aid in the development of appropriate treatment. Additionally, both of these kits sequence full-length transcripts enabling cell-type identification as well as providing detailed information on isoform changes, SNPs, or splice variants that can help us better understand the response to the infection and treatments alike.

To read studies by COVID-19 researchers using the kits below, please refer to the "RNA-seq" section of our COVID Publications page.

Cat. #

Product

Size

Price

License

Quantity

Details

634444

SMART-Seq® Stranded Kit

96 Rxns

USD $4854.00

License Statement

ID Number
392	This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents.
395	This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Additional information may be found at https://www.takarabio.com/patents.
425	LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
450	This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMART-Seq Stranded Kit is used to generate strand-specific RNA-seq libraries for Illumina® sequencing from 1–1,000 sorted cells or 10 pg–10 ng of purified total RNA. This kit incorporates Takara Bio's SMART (Switching Mechanism at the 5' end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. In addition, contrary to the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing and SMART-Seq HT Kit, reverse transcription is initiated using random priming instead of oligo(dT) priming, thus capturing the full transcriptome instead of only the polyadenylated fraction. The SMART-Seq Stranded Kit was specifically designed to deliver highly sensitive and reproducible data from single cells while keeping the workflow short and user friendly. The kit does not require additional rRNA removal methods or kits and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA-typically present in high abundance following cDNA synthesis from total RNA inputs-makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Components

634442

SMART-Seq® Stranded Kit

12 Rxns

USD $1106.00

License Statement

ID Number
395	This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Additional information may be found at https://www.takarabio.com/patents.
425	LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392	This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents.
450	This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

Notice to purchaser

Components

634485

SMARTer® Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

24 Rxns

USD $2600.00

License Statement

ID Number
425	LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392	This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents.
395	This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Additional information may be found at https://www.takarabio.com/patents.
450	This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

The SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries for Illumina sequencing from 250 pg–10 ng inputs of purified total RNA or from 10–1,000 intact cells. This kit incorporates Takara Bio’s proprietary SMART (Switching Mechanism at the 5’ end of RNA Template) technology and includes refinements to the SMARTer method for stranded RNA-seq that simplify the library preparation workflow and improve sequencing performance. This method was developed to work with either high- or low-quality total RNA, does not require additional rRNA removal methods or kits, and produces sequencing libraries that retain strand-of-origin information. The integrated removal of cDNAs derived from rRNA—typically present in high abundance following cDNA synthesis from total RNA inputs—makes the workflow extremely sensitive, yielding data that is highly reproducible with low mapping to rRNA. The new library design featured in this updated kit adds an 8 nucleotide (nt) unique molecular identifier (UMI) through the reverse-transcription step to mitigate potential PCR bias as well as to provide customers with additional information for transcript quantification, specifically for true variants and rare mutations. This kit includes the SMARTer RNA Unique Dual Index Kit - 24U (Takara Bio, Cat. No. 634451). SMARTer RNA Unique Dual Index Kit – 96U Set A and B (Cat. #s 634452, and 634457) are available for purchase. Together they offer up to 192 unique dual indexes for multiplexing.

Notice to purchaser

Components

634487

SMARTer® Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

96 Rxns

USD $5330.00

License Statement

ID Number
425	LIMITED USE LABEL LICENSE: RESEARCH USE ONLY Notice to Purchaser: This product is the subject to a license granted to Takara Bio USA, Inc. and its Affiliates from Caribou Biosciences, Inc., and this product is transferred to the end-user purchaser (“Purchaser”) subject to a “Limited Use Label License” conveying to the Purchaser a limited, nontransferable right to use the product, solely as provided to Purchaser, together with (i) progeny or derivatives of the product generated by the Purchaser (including but not limited to cells), and (ii) biological material extracted or derived from the product or its corresponding progeny or derivatives (including but not limited to cells) (collectively, the product, and (i) and (ii) are referred to as “Material”) only to perform internal research for the sole benefit of the Purchaser. The Purchaser cannot sell or otherwise transfer Material to a third party or otherwise use the Material for any Excluded Use. “Excluded Use” means any and all: (a) commercial activity including, but not limited to, any use in manufacturing (including but not limited to cell line development for purposes of bioproduction), product testing, or quality control; (b) preclinical or clinical testing or other activity directed toward the submission of data to the U.S. Food and Drug Administration, or any other regulatory agency in any country or jurisdiction where the active agent in such studies comprises the Material; (c) use to provide a service, information, or data to a third party with the sole exception of using the Material to conduct in vitro sample preparation, i.e., selectively depleting target cDNAs from a sample either by cleaving or selectively separating such target cDNAs from the sample through the use of the Materials; (d) use for human or animal therapeutic, diagnostic, or prophylactic purposes or as a product for therapeutics, diagnostics, or prophylaxis; (e) activity in an agricultural field trial or any activity directed toward the submission of data to the U.S. Department of Agriculture or any other agriculture regulatory agency; (f) high throughput screening drug discovery purposes (i.e., the screening of more than 10,000 experiments per day) as well as scale-up production activities for commercialization; (g) modification of human germline, including editing of human embryo genomes (with the sole exception of editing human embryonic stem (ES) cell lines for research purposes) or reproductive cells; (h) self-editing; and/or (i) stimulation of biased inheritance of a particular gene or trait or set of genes or traits (“gene drive”). It is the Purchaser’s responsibility to use the Material in accordance with all applicable laws and regulations. For information on obtaining additional rights, including commercial rights, please contact licensing@cariboubio.com or Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 USA, Attn: Licensing
392	This Product is protected by one or more patents from the family consisting of:US10941397, People's Republic of China Patent: ZL201480057094.4, US10781443, US10954510, DE602014069266.4, EP3058104, FR3058104, UK3058104, JP6602294, SE3058104, CA2923812, and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Information on relevant patents and licenses for this product may be found at: https://www.takarabio.com/patents.
395	This Product is protected by one or more patents from the family consisting of: US10150985, CA2939621, People's Republic of China Patent: ZL201480077658.0, US10988796, DE602014058059.9, EP3105325, FR3105325, UK3105325, JP6416939 and any corresponding patents, divisionals, continuations, patent applications and foreign filings sharing common priority with the same family. Additional information may be found at https://www.takarabio.com/patents.
450	This Product is sold under license from JumpCode Genomics, Inc., and is covered by one or more of the following US patents and foreign counterparts as well as pending US and foreign patent applications: 10,604,802; 11,708,606; 11,761,039; PCT/US2015/014242; CA2938669; EP 20192599.7; HK402021031164.3.

Notice to purchaser

Components

Overview

For additional product information and a full listing of available sizes, please visit:

More Information

References

Kustin, T. et al. A method to identify respiratory virus infections in clinical samples using next-generation sequencing. Sci. Rep. 9, 1–8 (2019).

Additional product information

Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.

Find more products for COVID-19 research

Helping researchers tackle COVID-19

Know your enemy: finding certainty in uncertain times

This blog highlights one of the first studies identifying and characterizing the novel coronavirus, ultimately contributing to the viral genome sequence being shared worldwide.

Screening for the novel coronavirus with one-step RT-qPCR

Learn how researchers identified a novel, highly contagious coronavirus and developed a one-step RT-qPCR screening protocol.

Takara Bio plays a crucial role in fighting the novel coronavirus

Learn how Takara employees in Dalian, China, are working tirelessly to keep up with the demand for the one-step PrimeScript RT-PCR kit, a crucial component in the detection of the novel coronavirus.

Entering new worlds while staying in place

Hear how a Product Manager in Europe is adjusting to the changing research market in light of COVID-19.

Working hard to meet production demands for SARS-CoV-2 testing

Hear how a Takara Bio employee of 27 years is contributing to the COVID-19 effort.

Dethroning king coronavirus with novel vaccines

Find out which types of SARS-CoV-2 vaccines are out there and how Takara Bio is joining the fight.

COVID-19 drug discovery

Our hiPSC-derived cells and other cell biology research products help you study SARS-CoV-2 infection, identify potential targets for drug discovery, evaluate the metabolism and safety of candidate drugs, and develop therapeutic approaches for COVID-19.

Takara Bio products in COVID-19 publications

An ever-growing compilation of COVID-19 publications using Takara Bio products and technologies.

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

Next-generation sequencing for SARS-CoV-2 research

Monitoring of the environment

Understanding the effects of viral infection

Notice to purchaser

634444: SMART-Seq Stranded Kit

Notice to purchaser

634442: SMART-Seq Stranded Kit

Notice to purchaser

634485: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

Notice to purchaser

634487: SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian

Overview

More Information

References

Additional product information

Find more products for COVID-19 research

Helping researchers tackle COVID-19